Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis

Prion

Volumn 5, Issue 1, 2011, Pages 16-21

  Galvin, James E ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Amyloid; Biomarkers; Dementia; Preclinical; Presymptomatic; Screening; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL DEMENTIA RATING SCALE; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GOLD STANDARD; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC DISEASE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROTEIN FOLDING; PROTEIN MISFOLDING; RATING SCALE; SCREENING; SENILE PLAQUE; SYMPTOM; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION DISORDERS; CREUTZFELDT-JAKOB SYNDROME; DEMENTIA; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; PLAQUE, AMYLOID; PROTEIN FOLDING; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 78651381462     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.5.1.14439     Document Type: Note

References (48)

1. Venneti S. Prion diseases. Clin Lab Med 2010; 30:293-309.
2. Sharma S, Mukherjee M, Kedage V, Muttigi MS, Rao A, Rao S. Sporadic Creutzfeldt-Jakob disease - a review. Int J Neurosci 2009; 119:1981-94.
3. Tarawneh R, Galvin JE. Distinguishing Lewy body dementias from Alzheimer's disease. Expert Rev Neurother 2007; 7:1499-516. (Pubitemid 350106830)
4. Tan JM, Wong ES, Lim KL. Protein misfolding and aggregation in Parkinson's disease. Antioxid Redox Signal 2009; 11:2119-34.
5. Bugiani O. The many ways to frontotemporal degeneration and beyond. Neurol Sci 2007; 28:241-4. (Pubitemid 350055432)
6. Cairns NJ, Ghoshal N. FUS: A new actor on the frontotemporal lobar degeneration stage. Neurology 2010; 74:354-6.
7. Alzheimer Association: 2010; Facts and Figures. http://www.alz.org. Accessed 11/15/10.
8. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66:1447-55.
9. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, et al. Alzheimer's Disease Neuroimaging Initiative: Serial MRI and CSF biomarkers in normal aging, MCI and AD. Neurology 2010; 75:143-51.
10. Funke SA, Birkmann E, Willbold D. Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease? Curr Alzheimer Res 2009; 6:285-9.
11. Galvin JE. Alzheimer disease: Understanding the challenges, improving the outcome. App Neurol 2007; 3-13.
12. Galvin JE. Alzheimer's disease: Diagnosis and treatment across the spectrum. App Neurol 2005; 1:1-16.
13. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009; 461:916-22.
14. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010; 223:334-46.
15. Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008; 4:38-48.
16. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009; 30:1026-36.
17. Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Storandt M, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol 2005; 62:758-65. (Pubitemid 40656091)
18. 11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67:446-52.
19. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66:1469-75.
20. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67:949-56.
21. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6:131-44.
22. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302:385-93.
23. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1:371-80.
24. Fagan A, Mintun M, Mach R, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and CSF Abeta42 in humans. Ann Neurol 2006; 59:512-9.
25. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9:119-28.
26. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403-13.
27. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64:343-9. (Pubitemid 46425688)
28. Hampel H, Broich K. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. J Nutr Health Aging 2009; 13:373-5.
29. Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimers Dis 2010; 610-3.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-44. (Pubitemid 14076461)
31. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-46.
32. Urbanelli L, Magini A, Ciccarone V, Trivelli F, Polidoro M, Tancini B, et al. New perspectives for the diagnosis of Alzheimer's disease. Recent Pat CNS Drug Discov 2009; 4:160-81.
33. Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ. Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis 2010; 7:131-5.
34. Brys M, Glodzik-Sobanska L, Switalski R, Rich K, Pirraglia E, Mosconi L, et al. MRI Improves CSF biomarkers in the early detection of Alzheimer's disease. J Alz Dis 2008; 16:351-62.
35. Wright CF, Hall A, Matthews FE, Brayne C. Biomarkers, dementia and public health. Ann NY Acad Sci 2009; 1180:11-9.
36. HR2959: Accountable Care Promotion Act of 2009; www.govtrack.us/congress/ bill.xpd?bill=h111-2959, Accessed 11/15/10.
37. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-19.
38. Haldenwanger A, Eling P, Kastrup A, Hildebrandt H. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI and Alzheimer's disease. J Alzheimers Dis 2010; 22:971-80.
39. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009; 66:1254-9.
40. Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC. Relationship of dementia screening tests with biomarkers of Alzheimer's Disease. Brain 2010; 133:3290-300.
41. Galvin JE, Roe C, Coats M, Powlishta KK, Muich SJ, Grant E, et al. The AD8: A brief informant interview to detect dementia. Neurology 2005; 65:559-64.
42. Galvin JE, Roe CM, Xiong C, Morris JC. The validity and reliability of the AD8 informant interview for dementia. Neurology 2006; 67:1942-8.
43. Folstein MF, Folstein SE, McHugh PR. Mini-mental State: A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 1975; 12:189-98.
44. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983; 140:734-9.
45. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-4.
46. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46:2740-54.
47. Glodzik-Sobanska L, Pirraglia E, Brys M, De Santi S, Mosconi L, Rich KE, et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 2009; 30:672-81.
48. Tarawneh R, Galvin JE. Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clinic Geriatr Med 2010; 26:125-47.